

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Vincent Medical Holdings Limited

永勝醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1612)

VOLUNTARY ANNOUNCEMENT FDA EMERGENCY USE AUTHORIZATION FOR INSPIRED™ HEAT AND MOISTURE EXCHANGING FILTER AND BACTERIAL/VIRAL RESPIRATOR FILTER AND HYPNUS™ POSITIVE AIRWAY PRESSURE DEVICE 8 SERIES

This announcement is made by Vincent Medical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis with the purpose of allowing the investing public to understand the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Group had recently received Emergency Use Authorization (“**EUA**”) from the Food and Drug Administration of the United States (“**FDA**”) for Inspired™ heat and moisture exchanging filter (the “**HMEF**”) and bacterial/viral respirator filter (the “**Bacterial/Viral Filter**”) (collectively the “**Filters**”) and Hypnus™ positive airway pressure device 8 series (the “**PAP 8 Series**”).

The Filters are medical consumables (for single patient use only and are required to be replaced every 24 hours) that serves as a key component for non-active breathing circuits for use with ventilators, anesthesia machines and open flow systems where filtration of inspired and/or expired gases is desired, so as to prevent cross contamination. For HMEF, also known as “artificial nose”, it can maintain moisture levels in the patient’s respiratory tract during anesthesia, artificial respiration and other types of assisted ventilation. The Filters were approved by the Japan’s Ministry of Health, Labour and Welfare and the National Medical Products Administration (the “**NMPA**”) of the People’s Republic of China and with the Conformité Européenne (CE) Mark. AutoMedx, LLC, a company in the United States of America, is the distributor for the Filters in the United States of America.

The PAP 8 Series is indicated to provide non-invasive positive airway pressure to spontaneously breathing patients weighing over 30 kg with Obstructive Sleep Apnea, and BPAP-T mode and BPAP-ST mode can be used for respiratory insufficiency. It is intended for hospital and home use and is not intended for patients dependent on mechanical ventilation. The PAP 8 Series was approved by the NMPA and with CE Mark.

During public health emergencies, FDA can use emergency authorities, including EUA, to make medical products available as quickly as possible by allowing unapproved medical products to reach patients in need when there are no adequate, FDA-approved and available alternatives. These products may include tests to help diagnose diseases, critical medical devices needed by patients or healthcare personnel in the context of a public health crisis, and drugs to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Vincent Medical Holdings Limited
Choi Man Shing
Chairman and Executive Director

Hong Kong, 30 June 2020

As at the date of this announcement, the Board comprises Mr. Choi Man Shing, Mr. To Ki Cheung, Mr. Koh Ming Fai and Mr. Fu Kwok Fu as executive Directors, Mr. Guo Pengcheng as a non-executive Director, and Mr. Mok Kwok Cheung Rupert, Mr. Au Yu Chiu Steven and Prof. Yung Kai Leung as independent non-executive Directors.